115 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02627 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : 3.2 ± 0.6 µM |
| dbacp02628 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | IC50 : 4.5 ± 0.5 µM |
| dbacp02629 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 4.7 ± 0.4 µM |
| dbacp02630 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 3.2 ± 0.4 µM |
| dbacp02688 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 17.44 - 49.51 μM |
| dbacp02689 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02690 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02691 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02692 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 17.44 - 49.51 μM |
| dbacp02693 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Brain tumor | IC50 : 7.44 μM |
| dbacp02694 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 7.44 μM |
| dbacp02695 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | pancreatic cancer | IC50 : 7.44 μM |
| dbacp02696 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 7.44 μM |
| dbacp02697 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 7.44 μM |
| dbacp02698 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Brain tumor | IC50 : 49.51 μM |
| dbacp02699 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 49.51 μM |
| dbacp02700 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 49.51 μM |
| dbacp02701 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 49.51 μM |
| dbacp02702 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 49.51 μM |
| dbacp02703 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Brain tumor | IC50 : 25.51 μM |
| dbacp02704 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 25.51 μM |
| dbacp02705 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 25.51 μM |
| dbacp02706 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 25.51 μM |
| dbacp02707 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 25.51 μM |
| dbacp02708 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 21.78 μM |
| dbacp02709 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 21.78 μM |
| dbacp02710 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 21.78 μM |
| dbacp02711 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 21.78 μM |
| dbacp02712 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 21.78 μM |
| dbacp02713 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 28.95 μM |
| dbacp02714 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 28.95 μM |
| dbacp02715 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 28.95 μM |
| dbacp02716 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 28.95 μM |
| dbacp02717 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 28.95 μM |
| dbacp02718 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Brain tumor | IC50 : 51.04 μM |
| dbacp02719 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 51.04 μM |
| dbacp02720 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 51.04 μM |
| dbacp02721 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 51.04 μM |
| dbacp02722 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 51.04 μM |
| dbacp02731 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 8.64 - 18.51 μM |
| dbacp02732 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02733 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02734 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02735 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp02736 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 8.64 - 18.51 μM |
| dbacp02737 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02738 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02739 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02740 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp03485 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Brain tumor | IC50 : 8.64μM |
| dbacp03486 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 8.64μM |
| dbacp03487 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Pancreatic cancer | IC50 : 8.64μM |
| dbacp03488 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 8.64μM |
| dbacp03489 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 8.64μM |
| dbacp03490 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Brain tumor | IC50 : 18.51μM |
| dbacp03491 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 18.51μM |
| dbacp03492 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 18.51μM |
| dbacp03493 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 18.51μM |
| dbacp03494 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 18.51μM |
| dbacp03495 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Brain tumor | IC50 : 9.88μM |
| dbacp03496 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 9.88μM |
| dbacp03497 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 9.88μM |
| dbacp03498 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 9.88μM |
| dbacp03499 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 9.88μM |
| dbacp03500 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 9.97μM |
| dbacp03501 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 9.97μM |
| dbacp03502 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 9.97μM |
| dbacp03503 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 9.97μM |
| dbacp03504 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 9.97μM |
| dbacp03505 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 11.17μM |
| dbacp03506 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 11.17μM |
| dbacp03507 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 11.17μM |
| dbacp03508 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 11.17μM |
| dbacp03509 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 11.17μM |
| dbacp03510 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Brain tumor | IC50 : 48.80μM |
| dbacp03511 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 48.80μM |
| dbacp03512 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 48.80μM |
| dbacp03513 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 48.80μM |
| dbacp03514 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 48.80μM |
| dbacp05525 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05526 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05527 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05528 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05529 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05530 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05531 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05532 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05533 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05534 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05535 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U251MG | Neurospongioma | IC50 : approx. 0.29 µM |
| dbacp05536 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05537 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05538 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05539 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05540 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05541 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05542 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05543 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05544 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05545 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05546 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U251MG | neurospongioma | IC50 : approx. 0.50 µM |
| dbacp06169 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | Not found |
| dbacp06170 | SVS-1 | KVKVKVKVpPTKVKVKVK | Bovine lactoferrin (Lf-B) | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | Not found |
| dbacp06171 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 8.1 ± 0.8 µM |
| dbacp06172 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 5.6 ± 0.5 µM |
| dbacp06173 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µM |
| dbacp06174 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | IC50 : >100 µM |
| dbacp06175 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µM |
| dbacp06176 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : >100 µM |
| dbacp06388 | Turgencin B | GIKEML_CnMACAQTVC_KKSGGPLCDTCQAACKALG-NH2 | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 4.1μM |
| dbacp06389 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06390 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV-NH2 | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06391 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06392 | Turgencin B | GIKEMLCnMACAQTVCKKSGGPLCDTCQAACKALG | Tunicate | Disruption of cell membranes | Human cell viability assay | A2059 | Melanoma cancer | IC50 : 4.1 μM |
| dbacp06393 | Turgencin B | GIKEMLCnMACAQTVCKKSGGPLCDTCQAACKALG | Tunicate | Disruption of cell membranes | Human cell viability assay | A2059 | Melanoma cancer | IC50 : 4.1 μM |